Skip to main content

Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

NEW YORK – Sema4 on Tuesday announced that it had entered into a research collaboration with Janssen to identify patients for enrollment onto Janssen's oncology clinical trials.

For its part of the collaboration, Stamford, Connecticut-based Sema4 will offer Janssen access to its genomics testing capabilities as well as its Centrellis health intelligence platform. Centrellis includes automated natural language processing and designated PhD oncology curators, among a suite of other tools used to extract information about key patient characteristics from electronic medical record data. Applying specific enrollment criteria for Janssen's clinical trials to its deidentified database of patients' clinical and genomic characteristics, Sema4 will help identify patients who may be eligible to participate in Janssen's clinical trials.

"We are delighted to collaborate with Janssen to utilize our technology and digital expertise and market-leading science experience to potentially accelerate trial recruitment times, with the goal of more treatment options becoming available to patients more quickly," Eric Schadt, Sema4's founder and CEO, said in a statement.

Sema4's collaboration with Janssen follows on the heels of a partnership announced earlier this year with artificial intelligence and informatics company VieCure, which provides a platform for oncology EMR and point-of-care decision support. The aim of the VieCure partnership is to enhance Sema4's national clinical trial support capabilities.

Also this year, the company launched Sema4 Signal, a line of bioinformatics tools and exome-based somatic and hereditary cancer genomic tests to support precision oncology, and in July, the company secured approval from the New York State Department of Health to conduct Signal's Whole Exome/Transcriptome Sequencing (WES/WTS) for solid and hematologic malignancies using tumor-normal analysis.